Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
169 hedge funds and large institutions have $318M invested in Clovis Oncology, Inc. in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 42 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
31% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 42
13% more call options, than puts
Call options by funds: $30.1M | Put options by funds: $26.5M
7% more funds holding
Funds holding: 158 → 169 (+11)
3% less capital invested
Capital invested by funds: $328M → $318M (-$9.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.5M |
| 2 |
N
Natixis
Paris,
France
|
+$6.52M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$5.98M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.44M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.15M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.51M |
| 4 |
Barclays
London,
United Kingdom
|
-$1.47M |
| 5 |
SGA
Sector Gamma AS
Oslo,
Norway
|
-$1.17M |
CLVS Hedge Fund Activity: Q3 2020 in Review
169 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2020, worth a combined $318M — down 2.9% from $328M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CLVS positions and 21 closed out — a net gain of 12 holders — while 55 added to existing stakes and 42 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $2.15M.
- 169 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2020, up from 158 in Q2 2020.
- Funds reported $318M of Clovis Oncology, Inc. stock for Q3 2020, down 2.9% quarter-over-quarter.
- 33 funds opened new Clovis Oncology, Inc. positions in Q3 2020 and 21 closed out, a net change of +12 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2020 was Morgan Stanley, an estimated $10.5M added.
- The largest Clovis Oncology, Inc. seller in Q3 2020 was Fidelity Investments, an estimated $2.15M sold.
Based on aggregated 13F filings for Q3 2020.